Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b randomized double-blind placebo-controlled study of MK-3655 in precirrhotic NASH
MOH_2020-11-29_009218Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of NGM313 in metabolic dysfunction-associated steatohepatitis (MASH) (4 arms), sponsored by Merck & Co. Started Oct 2020; status: completed.
02
Drugs
NGM313
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on MOH_2020-11-29_009218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-11-29_009218.